DOCSLIB.ORG

Novel Pathways Promoting Thyroid Tumourigenesis and Growth

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Novel Pathways Promoting Thyroid Tumourigenesis and Growth NOVEL PATHWAYS PROMOTING THYROID TUMOURIGENESIS AND GROWTH By Gregory Douglas Lewy A thesis presented to the College of Medical and Dental Sciences at the University of Birmingham for the Degree of Doctor of Philosophy Centre for Endocrinology, Diabetes and Metabolism, School of Clinical and Experimental Medicine March 2012 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. SUMMARY Thyroid cancers are the most common endocrine malignancies and their incidence continues to rise. Over-expression of the human pituitary tumor transforming gene (hPTTG) in thyroid carcinomas is a prognostic indicator of tumour recurrence. hPTTG is multifunctional with roles in mitotic control, DNA repair, genetic instability, cell transformation and apoptosis. Importantly, hPTTG transactivates expression of growth factors implicated in proliferation and angiogenesis, and represses the sodium iodide symporter (NIS), which is essential to radioiodine treatments in thyroid cancer. hPTTG interacts with a binding factor (PBF) which is an independent transforming gene and also represses iodine uptake. Work described in this thesis provides evidence for the existence of thyroidal autocrine regulatory pathways involving hPTTG and growth factors in vitro. We directly investigated the role of hPTTG in thyroid tumourigenesis through the generation and characterisation of a murine transgenic model with thyroid-targeted hPTTG over-expression (hPTTG-Tg mice). Unexpectedly, hPTTG over-expression was not sufficient for thyroid tumourigenesis. Investigations performed in hPTTG-Tg and Pttg-/- knockout mice indicated a particularly important relationship between hPTTG and the epidermal growth factor (EGF) in vivo. hPTTG and PBF were confirmed as repressors of NIS in vivo following studies in hPTTG-Tg and PBF-Tg mice respectively. The studies described in this thesis highlight the therapeutic potential of targeting hPTTG and PBF in thyroid cancer. To this effect, specific tyrosine kinase inhibitors prevented autocrine induction of hPTTG by growth factors, and siRNA depletion of PBF restored NIS function to normal levels in hPBF-Tg thyrocytes. Based on these data, hPTTG appears to play a dual role in endocrine tumourigenesis, being involved in both tumour initiation and subsequent progression towards more aggressive phenotypes. DEDICATION I would like to dedicate this Doctoral dissertation to my parents, Oliver and Sandy, and to my sister, Natalie. Thank you for your continual love and support. ACKNOWLEDGEMENTS I would like to express my sincere thanks to Dr Kristien Boelaert and Professor Chris McCabe for their inspiration, guidance, encouragement and for being all-round fantastic supervisors and also to Professor Jayne Franklyn for her support and commitment to this research. I would like to thank Dr. Martin Read for his patience and willingness to share his knowledge and expertise throughout the entire project. Further thanks to Martin and also to Gavin Ryan for their assistance during many hours of work at the Biomedical Services Unit (BMSU). Thanks to Dr. Andrea Bacon for her supporting expertise in murine transgenesis, Dr. Adrian Warfield for supporting histopathological analysis, to Mr. John Watkinson for providing thyroid specimens and to the BMSU staff for training and support. My gratitude to Dr. Margaret Eggo for her generosity in coaching me primary cell culture and associated techniques, as well as her infectious enthusiasm for this project. Thanks to all the friends I have made on IBR level 2 who have all been supportive and made my PhD an enjoyable experience. Particular thanks to the T.O.A.D Society for the banter, the practical jokes and the games, KURC FC and the exercise regimes, but most of all....the Row of Justice! I would also like to thank all of my friends outside of science who are always there, always planning something exciting and unknowingly providing much escapism and happiness. This work was funded by the Medical Research Council. ABBREVIATIONS ABT1 Activator of basal transcription 1 AFP Alpha-fetoprotein AIT Apical iodide transporter AITD Auto-immune thyroid disease AKT1 V-akt murine thymoma viral oncogene homolog 1 AP1 Activator protein 1 AP2 Activator protein 2 APC Anaphase promoting complex BRAF Serine/threonine-protein kinase CAM Chorio-allantoic membrane CAT Chloroamphenicol acetyltransferase cAMP Cyclic adenosine monophosphate CCNB1 Cyclin B CDC-2 Cyclin-dependent kinase 2 CDC-20 Cyclin-dependent kinase 20 CDE Cell cycle dependent element CDH1 Cadherin-1 CDK4 Cyclin-dependent kinase 4 CHR Cell cycle homology region CIN Chromosomal instability CRK V-crk sarcoma virus CT10 oncogene homolog CTNNB1 Catenin (cadherin-associated protein), beta 1 DB Destruction box DES Diethylstilbestrol DNA-PK DNA-dependent protein kinase ECM Extracellular matrix EGF Epidermal growth factor EGFR Epidermal growth factor receptor ERα Oestrogen receptor alpha EREs Oestrogen receptor elements ESCC Esophageal squamous cell carcinoma EST 17β-estradiol FGF-2 Fibroblast growth factor 2 FISSR-PCR Fluorescent inter-simple sequence repeat PCR FLT-1 Vascular endothelial growth factor receptor 1 FNA Fine needle aspiration FNAC Fine needle aspiration cytology FGFR1-4 Fibroblast growth factor receptor (1-4) GH Growth hormone HAT Histone acetyltransferase HCC Hepatocellular carcinoma HDAC Histone deacetylase HEK293 Human embryonic kidney 293 HGF Hepatocyte growth factor HLGAGs Heparin-like glycosaminoglycans hNUE Human upstream enhancer element hPTTG Human pituitary tumor transforming gene HRAS Harvey rat sarcoma viral oncogene HSP70 Heat shock protein 70 HUVEC Human umbilical vein endothelial cells ID3 Inhibitor of DNA-binding 3 IFNγ Interferon gamma IGF-1 Insulin-like growth factor 1 IL-1α Interleukin 1 alpha IL-1β Interleukin 1 beta IL-6 Interleukin 6 IL-8 Interleukin 8 KDR Vascular endothelial growth factor receptor 2 KRAS Kirsten rat sarcoma viral oncogene LB Lysogeny broth LH Luteneising hormone MAD2 Mitotic arrest deficient 2 MAPK Mitogen-activated protein kinase MEFs Mouse embryonic fibroblasts MEK1 Mitogen-activated protein kinase kinase 1 MEK3 Mitogen-activated protein kinase kinase 3 M-FISH Multiplex fluorescent in situ hybridisation MMP-2 Matrix metalloproteinase 2 MNG Multinodular goitre MRI Magnetic resonance imaging NF-Y Nuclear factor Y NGF Nerve growth factor NHEJ Non-homologous DNA end-joining NLS Nuclear localisation signal NIS Sodium iodide symporter NRAS Neuroblastoma rat sarcoma viral oncogene NTRK1 Neurotrophic tyrosine receptor kinase type 1 OCT-1 Octamer-binding transcription factor 1 PAX8 Paired box gene 8 PBF Pituitary tumor transforming gene binding factor PCNA Proliferating cell nuclear antigen PET Positron emission topography PI3K Phosphoinositide-3-kinase PIK3CA Phosphoinositide-3-kinase catalytic alpha polypeptide PKC Protein kinase C PKCβ1 Protein kinase C beta PLCγ Phospholipase C gamma PLK1 Polo-like kinase 1 PPARγ1 Peroxisome proliferator-activator receptor gamma 1 PRL Prolactin PTCs Papillary thyroid carcinomas PTEN Phosphatase and tensin homologue PTTG Pituitary tumor transforming gene PTTG1IP Pituitary tumor transforming gene 1 interacting protein (PBF) RAR-β Retinoic acid receptor beta RET Rearranged in transformation RET/PTC Rearranged in transformation/Papillary thyroid carcinomas shRNA Short hairpin ribonucleic acid SH-3 Src-homology-3 SP1 Specificity protein 1 T3 Triiodothyronine T4 Thyroxine TBPL1 TATA box-binding protein-like protein 1 TCF-4 Transcription factor 4 TG Thyroglobulin TGF-α Transforming growth factor alpha TGF-β Transforming growth factor beta TNF-α Tumor necrosis factor alpha TNF-β Tumor necrosis factor beta TNM Tumour size, node metastases and distant metastases TP53 Tumour protein p53 TPO Thyroid peroxidase TRα Thyroid hormone receptor alpha TRβ Thyroid hormone receptor beta TSHR Thyroid stimulating hormone receptor TSP-1 Thrombo-spondin 1 TSH Thyroid stimulating hormone TTF1 Thyroid transcription factor 1 USF1 Upstream stimulatory factor 1 VEGF Vascular endothelial growth factor WT Wild-type TABLE OF CONTENTS 1 CHAPTER ONE General Introduction ................................................................................................................... 0 1.1 Pathogenesis of thyroid cancer ............................................................................................ 1 1.1.1 Epidemiology and classification .................................................................................................1 1.1.2 Molecular genetics of thyroid cancer ..........................................................................................2 1.1.3 Oncogenes in thyroid cancer ......................................................................................................3 1.1.3.1 Tyrosine receptor kinase rearrangements................................................................................4 1.1.3.2 Nuclear receptor mutants .......................................................................................................4 1.1.3.3 RAS
Load more

Recommended publications
  • Therapeutic Targeting of the IGF Axis
    cells Review Therapeutic Targeting of the IGF Axis Eliot Osher and Valentine M. Macaulay * Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK * Correspondence: [email protected]; Tel.: +44-1865617337 Received: 8 July 2019; Accepted: 9 August 2019; Published: 14 August 2019 Abstract: The insulin like growth factor (IGF) axis plays a fundamental role in normal growth and development, and when deregulated makes an important contribution to disease. Here, we review the functions mediated by ligand-induced IGF axis activation, and discuss the evidence for the involvement of IGF signaling in the pathogenesis of cancer, endocrine disorders including acromegaly, diabetes and thyroid eye disease, skin diseases such as acne and psoriasis, and the frailty that accompanies aging. We discuss the use of IGF axis inhibitors, focusing on the different approaches that have been taken to develop effective and tolerable ways to block this important signaling pathway. We outline the advantages and disadvantages of each approach, and discuss progress in evaluating these agents, including factors that contributed to the failure of many of these novel therapeutics in early phase cancer trials. Finally, we summarize grounds for cautious optimism for ongoing and future studies of IGF blockade in cancer and non-malignant disorders including thyroid eye disease and aging. Keywords: IGF; type 1 IGF receptor; IGF-1R; cancer; acromegaly; ophthalmopathy; IGF inhibitor 1. Introduction Insulin like growth factors (IGFs) are small (~7.5 kDa) ligands that play a critical role in many biological processes including proliferation and protection from apoptosis and normal somatic growth and development [1]. IGFs are members of a ligand family that includes insulin, a dipeptide comprised of A and B chains linked via two disulfide bonds, with a third disulfide linkage within the A chain.
    [Show full text]
  • Co-Targeting HER2/Erbb2 and Insulin-Like Growth Factor-1
    Signature: Med Sci Monit, 2002; 8(12): BR521-526 WWW.MEDSCIMONIT.COM PMID: 12503030 Basic Research Received: 2002.11.08 Accepted: 2002.11.20 Co-targeting HER2/ErbB2 and insulin-like growth BR Published: 2002.12.27 factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells Authors’ Contribution: A Study Design abcdef b AG B Data Collection Anne Camirand , Yuhong Lu , Michael Pollak C Statistical Analysis D Data Interpretation Department of Oncology, McGill University, Montréal, QC, Canada E Manuscript Preparation F Literature Search Source of support: Streams of Excellence program of the Canadian Breast Cancer Research Institute. G Funds Collection Summary Background: The humanized anti-HER2 monoclonal antibody trastuzumab (Herceptin®) is useful in the treatment of ErbB2-overexpressing breast cancers, but its efficiency is limited because devel- opment of resistance is common. In order to study the possibility of improving the efficacy of therapies directed against HER2/erbB2, we investigated the effects of co-targeting this recep- tor and the insulin-like growth factor 1 receptor (IGF-1R), a widely-expressed protein tyro- sine kinase with important roles in suppression of apoptosis and stimulation of proliferation. Material/Methods: The experimental strategy involved combining trastuzumab treatment and reduction of IGF- 1R signaling through incremental heat-induced expression of the dominant-negative IGF-1 receptor 486/STOP under the control of the heat-sensitive Drosophila HSP70 promoter, in HER2/erbB2-overexpressing MCF7her18 breast cancer cells. Results: Isobologram analysis of combinatorial treatment data revealed a strong synergistic interaction between trastuzumab treatment and the induction of the dominant-negative IGF-1R expres- sion, resulting in potentiation of growth inhibition in transfected cancer cells.
    [Show full text]
  • Development and Preclinical Evaluation of Cixutumumab Drug
    www.nature.com/scientificreports OPEN Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF‑1R) positive cancer Viswas Raja Solomon1, Elahe Alizadeh1, Wendy Bernhard2, Amal Makhlouf1,3, Siddesh V. Hartimath1, Wayne Hill2, Ayman El‑Sayed2, Kris Barreto2, Clarence Ronald Geyer 2 & Humphrey Fonge1,4* Overexpression of insulin growth factor receptor type 1 (IGF‑1R) is observed in many cancers. Antibody drug conjugates (ADCs) with PEGylated maytansine (PEG6‑DM1) show promise in vitro. We developed PEG6‑DM1 ADCs with low and high drug to antibody ratios (DAR) using an anti‑ IGF‑1R antibody cixutumumab (IMC‑A12). Conjugates with low (cixutumumab‑PEG6‑DM1‑Low) and high (cixutumumab‑PEG6‑DM1‑High) DAR as 3.4 and 7.2, respectively, were generated. QC was performed by UV spectrophotometry, HPLC, bioanalyzer, and biolayer‑interferometry. We compared the in vitro binding and internalization rates of the ADCs in IGF‑1R‑positive MCF‑7/Her18 cells. We radiolabeled the ADCs with 111In and used microSPECT/CT imaging and ex vivo biodistribution to understand their in vivo behavior in MCF‑7/Her18 xenograft mice. The therapeutic potential of the ADC was studied in vitro and in mouse xenograft. Internalization rates of all ADCs was high and increased over 48 h and EC50 was in the low nanomolar range. MicroSPECT/CT imaging and ex vivo 111 biodistribution showed signifcantly lower tumor uptake of In‑cixutumumab‑PEG6‑DM1‑High 111 111 compared to In‑cixutumumab‑PEG6‑DM1‑Low and In‑cixutumumab. Cixutumumab‑PEG6‑DM1‑ Low signifcantly prolonged the survival of mice bearing MCF‑7/Her18 xenograft compared with cixutumumab, cixutumumab‑PEG6‑DM1‑High, or the PBS control group.
    [Show full text]
  • Interactions Between EGF and the IGF-1 Receptor in Mediating Hgly2-GLP-2-Induced Proliferation in the Murine Small Intestine
    Interactions Between EGF and the IGF-1 Receptor in Mediating hGly2-GLP-2-Induced Proliferation in the Murine Small Intestine by Zivit Fesler A thesis submitted in conformity with the requirements for the degree of Master’s of Science Department of Physiology University of Toronto © Copyright by Zivit Fesler 2019 Interactions Between EGF and the IGF-1 Receptor in Mediating hGly2-GLP-2-Induced Proliferation in the Murine Small Intestine Zivit Fesler Master’s of Science Department of Physiology University of Toronto 2019 Abstract Glucagon-like peptide-2 (GLP-2) is an intestinotrophic hormone that promotes intestinal proliferation through downstream mediators. Two known mediators are insulin-like growth factor-1 (IGF-1) and epidermal growth factor (EGF), both essential for the proliferative effect of GLP-2. I hypothesized that pre- and/or co-EGF enhances IGF-1-mediated GLP-2-induced proliferation in the murine model. Chronic combination treatment of EGF and GLP-2 increased intestinal growth in C57Bl/6 mice compared to vehicle, GLP-2 and respective EGF treatments. Treatment of pre-EGF+co-EGF+GLP-2 in intestinal epithelial IGF-1 receptor (IGF-1R) knockout mice restored intestinal growth despite the lack of a receptor essential for GLP-2 signaling. Finally, IGF-1 treatment in organoids did not have an additive effect to EGF on proliferation, but managed to replace EGF as an essential growth factor in the media to maintain normal proliferation. Together, these data suggest that exogenous EGF is an essential mediator for GLP-2 that can supersede the missing signaling pathway of IGF-1R. ii Acknowledgments Graduate school has been an important learning and growing environment for me.
    [Show full text]
  • Insulin-Like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells
    Research Article Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells Rita Nahta,1 Linda X.H. Yuan,1 Bing Zhang,1 Ryuji Kobayashi,2 and Francisco J. Esteva1,3,4 Departments of 1Breast Medical Oncology, 2Molecular Pathology, and 3Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center and 4The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas Abstract against the extracellular domain of the human epidermal growth The majority of breast cancer patients who achieve an factor (EGF) receptor 2 (HER-2) tyrosine kinase receptor (2). initial therapeutic response to the human epidermal growth Clinical studies established that trastuzumab is active against factor receptor 2 (HER-2)–targeted antibody trastuzumab HER-2-overexpressing metastatic breast cancers (3–5), leading to will show disease progression within 1 year. We previously its approval in 1998 by the U.S. Food and Drug Administration. reported the characterization of SKBR3-derived trastuzumab- However, the objective response rates to trastuzumab mono- resistant pools. In the current study, we show that HER-2 therapy are quite low, ranging from 12% to 34% for a median interacts with insulin-like growth factor-I receptor (IGF-IR) duration of 9 months (4, 5). The majority of patients who achieve an initial response to trastuzumab-based therapy acquire uniquely in these resistant cells and not in the parental trastuzumab-sensitive cells. The occurrence of cross talk resistance within 1 year of treatment initiation (6, 7). Elucidating between IGF-IR and HER-2 exclusively in resistant cells is the mechanisms by which tumors escape the cytotoxic properties evidenced by the IGF-I stimulation resulting in increased of trastuzumab is critical to improving the survival of metastatic phosphorylation of HER-2 in resistant cells, but not in breast cancer patients whose tumors overexpress HER-2.
    [Show full text]
  • Co-Targeting IGF-1R and C-Kit: Synergistic Inhibition of Proliferation and Induction of Apoptosis in H 209 Small Cell Lung Cancer Cells
    British Journal of Cancer (2004) 90, 1825 – 1829 & 2004 Cancer Research UK All rights reserved 0007 – 0920/04 $25.00 www.bjcancer.com Short Communication Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells 1 *,1 A Camirand and M Pollak 1Lady Davis Institute for Medical Research and Department of Oncology, McGill University, Montre´al, QC, Canada Most small cell lung cancers (SCLC) coexpress the c-kit protein tyrosine receptor kinase and its ligand stem cell factor, resulting in an autocrine loop. As SCLC growth is also driven by insulin-like growth factor-1 receptor (IGF-1R) signalling, tyrphostins AG 1024 and 1296 (inhibitors of IGF-1R and c-kit activity, respectively) were used to co-target these receptors in H 209 SCLC cells. Combination treatment caused synergy in proliferation inhibition and in apoptosis induction, and also enhanced reduction in phosphorylation of Erk1/Erk2, suggesting that co-targeting IGF-1R and c-kit in SCLC may be more effective than single-agent therapies. British Journal of Cancer (2004) 90, 1825 – 1829. doi:10.1038/sj.bjc.6601682 www.bjcancer.com Published online 20 April 2004 & 2004 Cancer Research UK Keywords: IGF-1R; c-kit; co-targeting; small cell lung cancer; synergy The signalling activity of receptor protein tyrosine kinases (PTKs) AG 1296 (which inhibits c-kit and PDGFR (Kovalenko et al,1994)) tightly controls crucial cellular processes such as apoptosis, and indolinones SU 5416 and SU6597 (inhibitors of c-kit and related differentiation and proliferation, and it is therefore not surprising kinases (Krystal et al, 2001)) reduce SCLC proliferation in vitro that deregulation of these molecules often leads to neoplastic (Krystal et al, 1997, 2000, 2001; Wang et al,2000;Kijimaet al, 2002).
    [Show full text]
  • Development and Diagnostic Application of a Novel Quantitative
    Development and Diagnostic Application of a Novel Quantitative Test for Determination and Characterization of Autoantibodies against Insulin-like Growth Factor 1 Receptor Inaugural-Dissertation to obtain the academic degree Doctor rerum naturalium (Dr. rer. nat.) submitted to the Department of Biology, Chemistry and Pharmacy of Freie Universität Berlin by TIM WELSINK from Düsseldorf 2014 Entwicklung und diagnostische Anwendung eines neuen Nachweisverfahrens zur Bestimmung und Charakterisierung von Autoantikörpern gegen den Insulin-like Growth Factor 1 Rezeptor Dissertation zur Erlangung des akademischen Grades des Doktors der Naturwissenschaften (Dr. rer. nat.) eingereicht im Fachbereich Biologie, Chemie, Pharmazie der Freien Universität Berlin vorgelegt von TIM WELSINK aus Düsseldorf 2014 This dissertation was prepared from 2010 to 2014 at the Institute for Experimental Endocrinology at Charité - Universitätsmedizin Berlin and has been supervised by Prof. Dr. Lutz Schomburg. Professor Dr. Markus Wahl has been the supervisor at the Institute for Chemistry and Biochemistry at Freie Universität Berlin. Angefertigt wurde diese Dissertation in den Jahren 2010 bis 2014 am Institut für Experimentelle Endokrinologie der Charité - Universitätsmedizin Berlin unter der Leitung von Prof. Dr. Lutz Schomburg. Betreut wurde diese Dissertation am Institut für Chemie und Biochemie der Freien Universität Berlin von Prof. Dr. Markus Wahl. 1. Gutachter (first referee): Prof. Dr. Lutz Schomburg 2. Gutachter (second referee): Prof. Dr. Markus Wahl Disputation am (disputation date) 13. April 2015 Summary / Zusammenfassung Summary / Zusammenfassung Summary Autoantibodies (aAb) are characteristic for autoimmune diseases. Specific aAb are often found both in diseased and apparently healthy individuals and may precede pathological symptoms. The contribution of thyrotropin receptor (TSHR) stimulating aAb to the progression of Graves´ Orbitopathy (GO) is widely accepted.
    [Show full text]
  • Estrogen Receptor Regulates Insulin-Like Growth Factor-I Receptor Gene Expression in Breast Tumor Cells: Involvement of Transcription Factor Sp1
    605 Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1 Sharon Maor, Doris Mayer1, Ronit I Yarden2, Adrian V Lee3, Rive Sarfstein, Haim Werner and Moshe Z Papa4 Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel 1Group on Hormones and Signal Transduction, German Cancer Research Center, Heidelberg D-69120, Germany 2Laboratory of Genomic Applications, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel 3Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA 4Department of Oncological Surgery, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel (Requests for offprints should be addressed to H Werner; Email: [email protected]) Abstract The insulin-like growth factors, IGF-I and IGF-II are a familyof along with the Sp1-family-binding inhibitor Mithramycin A. mitogenic polypeptides with important roles in growth and The results obtained indicate that basal IGF-IR promoter differentiation. The biological actions of the IGFs are mediated activity was 5.8-fold higher in MCF-7 than in C4 cells. Estradiol by the IGF-I receptor (IGF-IR), a cell-surface tyrosine kinase, treatment significantly activated the IGF-IR promoter in whose activation by serum IGF-I seems to be a key step in breast MCF-7, but not in C4 cells. Furthermore, the estrogen cancer initiation. Evidence accumulated indicates that estrogens responsive region in the IGF-IR promoter was mapped to a stimulate the expression and activity of IGF axis components. GC-rich sequence located between nucleotides K40 and The aim of our study was to examine the transcriptional K188 in the 50 flanking region.
    [Show full text]
  • Drug Delivery Approaches for Breast Cancer
    Journal name: International Journal of Nanomedicine Article Designation: Review Year: 2017 Volume: 12 International Journal of Nanomedicine Dovepress Running head verso: Singh et al Running head recto: Drug delivery for breast cancer open access to scientific and medical research DOI: http://dx.doi.org/10.2147/IJN.S140325 Open Access Full Text Article REVIEW Drug delivery approaches for breast cancer Santosh Kumar Singh1 Abstract: Breast cancer is one of the most common cancers affecting women worldwide. The Shriti Singh2 controlled release of drugs to the precise site of the disease using a nanocarrier vehicle increases James W Lillard Jr1 the therapeutic efficiency of the drugs. Nanotechnology-based approaches used to endorse Rajesh Singh1 clinical improvement from a disease also help to understand the interaction of malignant cells with their microenvironment. Receptor-based targeting is another approach for drug delivery 1Department of Microbiology, Biochemistry and Immunology, which is undergoing clinical trials. Nanoparticles (NPs) delivery has been proven to promise high Morehouse School of Medicine, loading capacity, less toxicity, and stability of the drugs or biomolecules compared to traditional 2 Atlanta, GA, USA; Department of chemotherapeutic drugs. The goal of this review is to present the current problems of breast Kriya Sharir, Institute of Medical Sciences, Banaras Hindu University, cancer therapy and discuss the NP-based targeting to overcome the hurdles of conventional Varanasi, India drug therapy approach. Keywords:
    [Show full text]
  • Characterization of Somatomedins from Human Fetal Brain
    Proc. Nad. Acad. Sci. USA Vol. 83, pp. 4904-4907, July 1986 Medical Sciences Characterization of somatomedins from human fetal brain: Identification of a variant form of insulin-like growth factor I (fetal growth/central nervous system) VICKI R. SARA*, CHRISTINE CARLSSONSKWIRUT*, CHARLOTTE ANDERSSON*, EVA HALL*, BARBRO SJ6GREN*, ARNE HOLMGRENt, AND HANS JORNVALLt *Karolinska Institute's Department of Psychiatry, St. Goran's Hospital, Box 12500, 112 81 Stockholm, Sweden; and tDepartment of Chemistry I, Karolinska Institute, 104 01 Stockholm, Sweden Communicated by RolfLuft, March 4, 1986 ABSTRACT A fetal form of somatomedin (insulin-like MATERIALS AND METHODS growth factor) that crossreacts in the fetal brain radioreceptor assay has been proposed to exist in humans. Using this assay to Preparation of Cytosol from Human Fetal Brain Tissue. monitor activity during purification, we have isolated a variant Immediately after legal prostaglandin abortion, fetuses were form of insulin-like growth factor I (IGF-I) from human fetal stored in sterile 0.9% NaCl at 40C. Within 12 hr, the whole brain tissue. The variant IGF-I showed potent crossreaction in fetal brain minus cerebellum was removed and stored at the fetal brain radioreceptor assay and stimulated DNA syn- -700C until use. Five volumes of 50 mM Tris Cl (pH 7.4) thesis in fetal brain cells in vitro. Structural analysis revealed containing 0.2 mM phenylmethylsulfonyl fluoride was added the variant IGF-I to have a truncated NH2-terminal region to frozen brain tissue which was then homogenized with a compared to IGF-I isolated from serum. An additional peptide, Polytron for 1 min.
    [Show full text]
  • Increased Insulin-Like Growth Factor I Binding to Red Blood Cells of Normal Prepubertal Children1
    003 1 -3998/89/2504-0409$02.00/0 PEDIATRIC RESEARCH Val. 25, No. 4, 1989 Copyr~ghtO 1989 International Pediatric Research Foundation, Inc. Prinred in U.S. A. Increased Insulin-Like Growth Factor I Binding to Red Blood Cells of Normal Prepubertal Children1 ALAN H. MORRIS, JON1 L. JOYCE, AND EDWARD 0. REITER Bayslnle iMedica1 Center, Depurtrnenl oJPediutrics, Sprindeld, Ma.ssuchusetts 01199 ABSTRACT. Young children are growing at a time when tractive to study because they are easily obtainable and require circulating levels of IGF-I measured by RIA are generally only small sample vol. less than or equal to values in nongrowing adults. '''I- In the present study, we compare IGF-I binding to erythrocytes Thr"-IGF-I binding to receptors on conveniently available in normal adults and prepubertal children, using a Thr59-IGF-I red blood cells was studied in 33 normal adults (nine males, analog. We wished to assess whether young children had evidence 24 females) and 13 normal prepubertal children aged 3-10 for greater binding of IGF-I to help explain their continuing y (10 boys, three girls; all Tanner stage I). Wed blood cell growth. specific binding of 12'I-Thr59-IGF-I was determined by displacement of labeled Thr"-IGF-I by unlabeled Thrs9- IGF-I or insulin in a dose-dependent manner. Mean (2 MATERIALS AND METHODS SEM) '2'I-Thr'9-IGF-I specific binding was significantly Subjects. We studied 13 normal children, 10 boys and three higher (p 0.01) in prepubertal children than in adults = girls, aged 3 to 10 y.
    [Show full text]
  • CURRICULUM VITAE: Carlos L. Arteaga, MD
    CURRICULUM VITAE: Carlos L. Arteaga, M.D. Personal Data Citizenship: U.S.A. Family Status: Married, four children Professional Address: UT Southwestern Harold C. Simmons Cancer Center 5323 Harry Hynes Blvd. Dallas, TX 75390-8590 Tel. 214-648-1677; Fax 214-648-7084 E-mail: [email protected] (simmonscancercenter.org) Education 1981 (M.D.) Facultad de Ciencias Médicas, Universidad de Guayaquil, Ecuador Post-Graduate Training 1984-1987 Fellowship in Medical Oncology and Hematology, University of Texas Health Science Center at San Antonio 1981-1984 Internship and Residency, Internal Medicine, Emory University Affiliate Hospitals Program, Atlanta, GA Professional Experience Sept. 2017 – Director, Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs, UT Southwestern Medical Center Sept. 2017 – Professor of Medicine, UT Southwestern Medical Center Sept. 2017 – The Lisa K. Simmons Distinguished Chair in Comprehensive Oncology Mar. 2013 – Aug. 2017 Director, Center for Cancer Targeted Therapies, Vanderbilt- Ingram Cancer Center (VICC) Sept. 2010 – Aug. 2017 Associate Director for Translational/Clinical Research VICC July 2010 – Oct 2011 Interim Director, Division of Hematology-Oncology, Vanderbilt University Medical Center Dec. 1998 – Aug. 2017 Professor of Medicine and Cancer Biology, Vanderbilt July 2009 – Aug. 2017 Donna S. Hall Chair in Breast Cancer Research Jan 1996 – Aug. 2017 Director, VICC Breast Cancer Program July 1995 - Sept 2000 Clinical Investigator, Department of Research & Development,
    [Show full text]